iStockAnand Rathi has hold call on Neogen Chemicals Ltd. with a target price of Rs 1650.0. The current market price of . is Rs 1427.3 Time period given by analyst is year when Neogen Chemicals Ltd. price can reach defined target. .
Neogen Chemicals Ltd., incorporated in the year 1989, is a Small Cap company (having a market cap of Rs 3561.71 Crore) operating in Chemicals sector.
Neogen Chemicals Ltd. key Products/Revenue Segments include Organic/Inorganic Heavy Chemicals and Other Operating Revenue for the year ending 31-Mar-2021.
Financials
For the quarter ended 31-03-2022, the company has reported a Consolidated Total Income of Rs 157.65 Crore, up 18.83 % from last quarter Total Income of Rs 132.67 Crore and up 70.03 % from last year same quarter Total Income of Rs 92.72 Crore. Company has reported net profit after tax of Rs 15.56 Crore in latest quarter.
Investment Rationale
Despite non-available RM issues, input-price volatility and supply-chain disruptions, Neogen’s FY22 revenue/EBITDA/PAT grew 45%/35%/42% y/y. We expect 27%/31%/43% CAGRs over FY22-24, driven by high-value added products, sharper focus on its CSM business, ramping up organic chemicals capacity and strong demand for pharma and agro-intermediates.
Promoter/FII Holdings
Promoters held 60.19 per cent stake in the company as of 31-Mar-2022, while FIIs owned 4.36 per cent, DIIs 18.64 per cent.
Neogen Chemicals Ltd., incorporated in the year 1989, is a Small Cap company (having a market cap of Rs 3561.71 Crore) operating in Chemicals sector.
Neogen Chemicals Ltd. key Products/Revenue Segments include Organic/Inorganic Heavy Chemicals and Other Operating Revenue for the year ending 31-Mar-2021.
Financials
For the quarter ended 31-03-2022, the company has reported a Consolidated Total Income of Rs 157.65 Crore, up 18.83 % from last quarter Total Income of Rs 132.67 Crore and up 70.03 % from last year same quarter Total Income of Rs 92.72 Crore. Company has reported net profit after tax of Rs 15.56 Crore in latest quarter.
Investment Rationale
Despite non-available RM issues, input-price volatility and supply-chain disruptions, Neogen’s FY22 revenue/EBITDA/PAT grew 45%/35%/42% y/y. We expect 27%/31%/43% CAGRs over FY22-24, driven by high-value added products, sharper focus on its CSM business, ramping up organic chemicals capacity and strong demand for pharma and agro-intermediates.
Promoter/FII Holdings
Promoters held 60.19 per cent stake in the company as of 31-Mar-2022, while FIIs owned 4.36 per cent, DIIs 18.64 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
now!Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by